Clinical-stage drug development company Woolsey Pharmaceuticals Inc reported on Wednesday that its BRAVYL (fasudil) has demonstrated positive results in a Phase 2a Amyotrophic Lateral Sclerosis (ALS) study.
BRAVYL significantly reduced Neurofilament Light (NfL), a marker of nerve cell damage, and showed trends towards improved clinical outcomes.
NfL levels decreased by 15% from baseline to 6 months. Since NfL in the ALS population tends to increase by a mean of 11% in 6 months, this suggests that 180 mg/day BRAVYL could potentially reduce NfL up to 26% versus placebo over 6 months.
Additionally, greater decreases in NfL were correlated with less decline in ALS functional scores, suggesting potential clinical benefits.
A separate analysis compared trial data with matched ALS patients. REAL patients showed slower decline in breathing capacity, muscle strength and ALS function compared to controls.
The trial is ongoing with a higher dose being evaluated for safety and efficacy.
Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn
Humacyte prices USD20m registered direct offering
Curia expands Glasgow manufacturing capacity and enhances CLD platform
Congruence Therapeutics secures USD39.5m financing
Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Mirecule expands collaboration with Sanofi to advance FSHD therapy
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics
Apertura Gene Therapy agrees manufacturing collaboration with Viralgen
Humacyte submits Israel MAA for Symvess arterial trauma repair
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment